Pharmacokinetics of maropitant citrate in New Zealand White rabbits (Oryctolagus cuniculus)

Sarah M. Ozawa 1William T. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Sarah M. Ozawa in
Current site
Google Scholar
PubMed
Close
 DVM
,
Michelle G. Hawkins 2Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Michelle G. Hawkins in
Current site
Google Scholar
PubMed
Close
 VMD
,
Tracy L. Drazenovich 2Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Tracy L. Drazenovich in
Current site
Google Scholar
PubMed
Close
 DVM
,
Philip H. Kass 3Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Philip H. Kass in
Current site
Google Scholar
PubMed
Close
 DVM, MPVM, PhD
, and
Heather K. Knych 4Department of the K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616.

Search for other papers by Heather K. Knych in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

OBJECTIVE

To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus).

ANIMALS

11 sexually intact (3 males and 8 females) adult rabbits.

PROCEDURES

Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored.

RESULTS

Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment.

CONCLUSIONS AND CLINICAL RELEVANCE

Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.

Abstract

OBJECTIVE

To determine the pharmacokinetics and adverse effects of maropitant citrate after IV and SC administration to New Zealand White rabbits (Oryctolagus cuniculus).

ANIMALS

11 sexually intact (3 males and 8 females) adult rabbits.

PROCEDURES

Each rabbit received maropitant citrate (1 mg/kg) IV or SC. Blood samples were collected at 9 (SC) or 10 (IV) time points over 48 hours. After a 2-week washout period, rabbits received maropitant by the alternate administration route. Pharmacokinetic parameters were calculated. Body weight, food and water consumption, injection site, mentation, and urine and fecal output were monitored.

RESULTS

Mean ± SD maximum concentration after SC administration was 14.4 ± 10.9 ng/mL and was detected at 1.25 ± 0.89 hours. Terminal half-life after IV and SC administration was 10.4 ± 1.6 hours and 13.1 ± 2.44 hours, respectively. Bioavailability after SC administration was 58.9 ± 13.3%. Plasma concentration at 24 hours was 2.87 ± 1.69 ng/mL after IV administration and 3.4 ± 1.2 ng/mL after SC administration. Four rabbits developed local dermal reactions at the injection site after SC injection. Increased fecal production was detected on the day of treatment and 1 day after treatment.

CONCLUSIONS AND CLINICAL RELEVANCE

Plasma concentrations of rabbits 24 hours after SC and IV administration of maropitant citrate (1 mg/kg) were similar to those of dogs at 24 hours. Reactions at the SC injection site were the most common adverse effect detected. Increased fecal output may suggest an effect on gastrointestinal motility. Additional pharmacodynamic and multidose studies are needed.

Contributor Notes

Address correspondence to Dr. Hawkins (mghawkins@ucdavis.edu).
  • 1. Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther 2013;36:462470.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2. Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther 2007;30:336344.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3. Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg 2013;40:2834.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4. Rau SE, Barber LG, Burgess KE. Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. J Vet Intern Med 2010;24:14521457.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5. Vail DM, Rodabaugh HS, Conder GA, et al. Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patients. Vet Comp Oncol 2007;5:3846.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6. Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31:220229.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7. Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014;94:265301.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8. Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther 2002;300:925931.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9. Greenwood-Van Meerveld B, Gibson MS, Johnson AC, et al. NK1 receptor-mediated mechanisms regulate colonic hyper-sensitivity in the guinea pig. Pharmacol Biochem Behav 2003;74:10051013.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10. Onori L, Agio A, Taddei G, et al. Peristalsis regulation by tachykin NK1 receptors in the rabbit isolated distal colon. Am J Physiol Gastrointest Liver Physiol 2003;285:G325G331.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11. AVMA. US pet ownership and demographics sourcebook. Schaumburg, Ill: AVMA, 2012.

  • 12. Meesters R, Voswinkel S. Bioanalytical method development and validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry. J Appl Bioanal 2018;4:6773.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13. Kenward H, Elliott J, Lee T, et al. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Vet Res 2017;13:244.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14. de la Puente-Redondo VA, Tilt N, Rowan TG, et al. Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. Am J Vet Res 2007;68:4856.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15. Steinbach JR, MacGuire J, Chang S, et al. Assessment of preoperative maropitant citrate use in macaque (Macaca fasicularis & Macaca mulatta) neurosurgical procedures. J Med Primatol 2018;47:178184.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16. Cram RL, Juchau MR, Fouts JR. Differences in hepatic drug metabolism in various rabbit strains before and after pretreatment with phenobarbital. Proc Soc Exp Biol Med 1965;118:872875.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 1980;8:165176.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18. Deckers N, Ruigrok CA, Verhoeve HP, et al. Comparison of pain response after subcutaneous injection of two maropitant formulations to Beagle dogs. Vet Rec Open 2018;5:e000262.

    • Search Google Scholar
    • Export Citation
  • 19. Narishetty ST, Galvan B, Coscarelli E, et al. Effect of refrigeration of the antiemetic Cerenia (maropitant) on pain on injection. Vet Ther 2009;10:93102.

    • Search Google Scholar
    • Export Citation
  • 20. Pfizer. Cerenia (maropitant citrate) injectable solution for cats. In: Freedom of information summary. New York: Pfizer Inc, 2012;141262.

    • Search Google Scholar
    • Export Citation
  • 21. Nakamura A, Tanaka T, Imanishi A, et al. Bidirectional regulation of human colonic smooth muscle contractility by tachykinin NK(2) receptors. J Pharmacol Sci 2011;117:106115.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement